
A post‐hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes. In PIONEER 9 and 10, patients were randomized to once‐daily oral semaglutide (3, 7 or 14 mg) or a comparator (placebo or once‐daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once‐weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10]) for 52 weeks, with 5 weeks’ follow up. In total, 701 patients were included (PIONEER 9: N=243; PIONEER 10: N=458). Glycaemic efficacy of oral semaglutide was similar in Japanese patients aged <65 years compared with those ≥65 years...
Like
Save
Share